Affiliation:
1. Monash Addiction Research Centre, Eastern Health Clinical School Monash University Melbourne Australia
2. Musculoskeletal Health and Sustainable Health Care Units, School of Public Health and Preventive Medicine Monash University Melbourne Victoria Australia
Abstract
AimsThis study aimed to evaluate whether voluntary and mandatory prescription drug monitoring program (PDMP) use in Victoria, Australia, had an impact on prescribing behaviour, focusing on individual patients' prescribed opioid doses and transition to prescribing of nonmonitored medications.MethodsThis was a retrospective cross‐sectional study using routinely collected primary healthcare data. A 90‐day moving average prescribed opioid dose in oral morphine equivalents was used to estimate opioid dosage. A Markov transition matrix was used to describe how patients prescribed medications transitioned between opioid dose groups and other nonopioid treatment options during 3 transition periods: transition between 2 control periods prior to PDMP implementation (T1 to T2); during the voluntary PDMP implementation (T2 to T3); and during mandatory PDMP implementation (T3 to T4).ResultsAmong patients prescribed opioids in our study, we noted an increased probability of transitioning to not being prescribed opioids during the mandatory PDMP period (T3 to T4). This increase was attributed mainly to the ceasing of low‐dose opioid prescribing. Membership in an opioid dose group remained relatively stable for most patients who were prescribed high opioid doses. For those who were only prescribed nonmonitored medications initially, the probability of being prescribed opioids increased during the mandatory PDMP when compared to other transition periods.ConclusionThe introduction of PDMP mandates appeared to have an impact on the prescribing for patients who were prescribed low‐dose opioids, while its impact on individuals prescribed higher opioid doses was comparatively limited.
Funder
National Health and Medical Research Council
Reference39 articles.
1. ChrzanowskaA ManN DegenhardtL DobbinsT PeacockA.Trends in drug‐related hospitalisations in Australia 1999–2019. Drug Trends Bulletin Series Sydney: National Drug and Alcohol Research Centre UNSW Sydney;2019.
2. Trends in heroin and pharmaceutical opioid overdose deaths in Australia
3. Deloitte.Regulatory impact statement—proposed drugs poisons and controlled substances amendment (real‐time prescription monitoring) regulations 2018.2018.
4. Prescription Drug Monitoring Programs and Prescription Opioid–Related Outcomes in the United States
5. No Shortcuts to Safer Opioid Prescribing